WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H558290
CAS#: 113276-96-3
Description: Valilactone is a fatty acid synthase inhibitor produced by a cultured strain of soil actinomycetes. Fatty acid synthase (FAS) is necessary for growth and survival of tumor cells and is a promising drug target for oncology.
Hodoodo Cat#: H558290
Name: Valilactone
CAS#: 113276-96-3
Chemical Formula: C22H39NO5
Exact Mass: 397.28
Molecular Weight: 397.556
Elemental Analysis: C, 66.47; H, 9.89; N, 3.52; O, 20.12
Synonym: Valilactone; (-)-Valilactone
IUPAC/Chemical Name: 1-((2S,3R)-3-hexyl-4-oxooxetan-2-yl)heptan-2-yl formyl-L-valinate
InChi Key: WWGVIIVMPMBQFV-HNNZKPGWSA-N
InChi Code: InChI=1S/C22H39NO5/c1-5-7-9-11-13-18-19(28-21(18)25)14-17(12-10-8-6-2)27-22(26)20(16(3)4)23-15-24/h15-20H,5-14H2,1-4H3,(H,23,24)/t17?,18-,19+,20+/m1/s1
SMILES Code: CC(C)[C@@H](C(OC(C[C@@H]([C@H]1CCCCCC)OC1=O)CCCCC)=O)NC=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 397.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Richardson RD, Ma G, Oyola Y, Zancanella M, Knowles LM, Cieplak P, Romo D, Smith JW. Synthesis of novel beta-lactone inhibitors of fatty acid synthase. J Med Chem. 2008 Sep 11;51(17):5285-96. doi: 10.1021/jm800321h. PubMed PMID: 18710210; PubMed Central PMCID: PMC3172131.
2: Ma G, Zancanella M, Oyola Y, Richardson RD, Smith JW, Romo D. Total synthesis and comparative analysis of orlistat, valilactone, and a transposed orlistat derivative: Inhibitors of fatty acid synthase. Org Lett. 2006 Sep 28;8(20):4497-500. PubMed PMID: 16986934.
3: Wu Y, Sun YP. An expeditious enantioselective total synthesis of valilactone. J Org Chem. 2006 Jul 21;71(15):5748-51. PubMed PMID: 16839158.
4: Yoshinari K, Aoki M, Ohtsuka T, Nakayama N, Itezono Y, Mutoh M, Watanabe J, Yokose K. Panclicins, novel pancreatic lipase inhibitors. II. Structural elucidation. J Antibiot (Tokyo). 1994 Dec;47(12):1376-84. PubMed PMID: 7844032.
5: Kitahara M, Asano M, Naganawa H, Maeda K, Hamada M, Aoyagi T, Umezawa H, Iitaka Y, Nakamura H. Valilactone, an inhibitor of esterase, produced by actinomycetes. J Antibiot (Tokyo). 1987 Nov;40(11):1647-50. PubMed PMID: 3693135.
